DINGDANG HEALTH TECHNOLOGY GROUP LTD. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.2 HKD | -4.00% |
|
+18.81% | -39.70% |
| Apr. 01 | Dingdang Health Technology Slashes Losses in 2023 | MT |
| Mar. 28 | Dingdang Health Technology Group Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Valuation
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Capitalization 1 | 13,791 | 2,426 | 1,490 | - |
| Enterprise Value (EV) 1 | 12,743 | 2,426 | 1,490 | 1,490 |
| P/E ratio | -3.05 x | -10.6 x | -15.9 x | -111 x |
| Yield | - | - | - | - |
| Capitalization / Revenue | 3.19 x | 0.5 x | 0.27 x | 0.25 x |
| EV / Revenue | 3.19 x | 0.5 x | 0.27 x | 0.25 x |
| EV / EBITDA | -71.7 x | -17.3 x | 32.4 x | 10.7 x |
| EV / FCF | -38,099,598 x | - | - | - |
| FCF Yield | -0% | - | - | - |
| Price to Book | 6.31 x | - | 0.77 x | 0.77 x |
| Nbr of stocks (in thousands) | 1,341,473 | 1,341,473 | 1,341,473 | - |
| Reference price 2 | 10.28 | 1.809 | 1.111 | 1.111 |
| Announcement Date | 3/28/23 | 3/28/24 | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Net sales 1 | - | 4,329 | 4,857 | 5,429 | 6,026 |
| EBITDA 1 | - | -192.4 | -140.6 | 46 | 139 |
| EBIT 1 | - | -327.7 | -280.6 | -83 | -2 |
| Operating Margin | - | -7.57% | -5.78% | -1.53% | -0.03% |
| Earnings before Tax (EBT) 1 | - | -2,832 | -221.2 | -94 | -13 |
| Net income 1 | -1,578 | -2,833 | -225.8 | -92 | -10 |
| Net margin | - | -65.45% | -4.65% | -1.69% | -0.17% |
| EPS 2 | -3.310 | -3.370 | -0.1700 | -0.0700 | -0.0100 |
| Free Cash Flow | - | -362 | - | - | - |
| FCF margin | - | -8.36% | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - |
| Announcement Date | 8/31/22 | 3/28/23 | 3/28/24 | - | - |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - |
| Net Cash position | - | 1,048 | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - |
| Free Cash Flow | - | -362 | - | - | - |
| ROE (net income / shareholders' equity) | - | - | - | -4.6% | -0.5% |
| ROA (Net income/ Total Assets) | - | - | - | -3% | -0.3% |
| Assets 1 | - | - | - | 3,067 | 3,333 |
| Book Value Per Share 2 | - | 1.630 | - | 1.450 | 1.440 |
| Cash Flow per Share 2 | - | - | - | 0.0100 | 0.0800 |
| Capex 1 | - | 17.7 | - | 79 | 79 |
| Capex / Sales | - | 0.41% | - | 1.46% | 1.31% |
| Announcement Date | 8/31/22 | 3/28/23 | 3/28/24 | - | - |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
1.111
CNY
Average target price
1.366
CNY
Spread / Average Target
+23.00%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -39.70% | 214M | |
| -32.09% | 15.55B | |
| -30.56% | 11.21B | |
| -30.19% | 6.23B | |
| +9.74% | 6B | |
| -9.65% | 5.89B | |
| +0.88% | 4.72B | |
| +53.60% | 4.32B | |
| -10.49% | 3.77B | |
| -12.53% | 3.4B |
- Stock Market
- Equities
- 9886 Stock
- Financials Dingdang Health Technology Group Ltd.
